Role of molecular biology in the management of pancreatic cancer

doi:10.4251/wjgo.v16.i7.2902

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2186)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

HTML

1443

Figures (1-2)

169

Tables (1-2)

176

Sum=1852

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

154

Sum=234

Jul 15, 2024 (publication date) through Feb 11, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Jul 15, 2024; 16(7): 2902-2914
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.2902

Table 1 Main actionable molecular alterations in pancreatic ductal adenocarcinoma and their current European Society for Medical Oncology scale for clinical actionability of molecular target classification

Biomarker	Targeted therapy	ESCAT classification	Ref.
BRCA1, BRCA2 germinal	Olaparib	IA	[87]
BRCA1, BRCA2 germinal/somatic	Rucaparib	IB	[86,88]
PALB2 germinal/somatic	Rucaparib	IB	[88]
NTRK fusions	Larotrectinib, entrectinib	IC	[27,89]
MSI high	Pembrolizumab	IC	[25]
RET fusions	Pralseltinib, selpercatinib	IC	[90,91]
NRG1 fusions	Zenocutuzumab	IIB	[30]
KRAS^G12C	Sotorasib, adagrasib	IIB	[55,56]
FGFR2 Fusions	Pemigatinib, infigratinib, futibatinib	IIIA	[92,93]
PIK3CA mutations	Alpelisib, buparlisib	IIIA	[94,95]
BRAF^V600Emutation	Dabrafenib + trametinib, Binimetinib + encorafenib	IIIA	[96,97]
ALK/ROS1 fusions	Crizotinib, ceritinib, alectinib	IIIA	[98-100]
ERBB2 amplification	Trastuzumab + pertuzumab, T-DM1	IIIA	[101,102]

ESCAT: European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets; MSI: Microsatellite instability.

Citation: Boileve A, Smolenschi C, Lambert A, Boige V, Tarabay A, Valery M, Fuerea A, Pudlarz T, Conroy T, Hollebecque A, Ducreux M. Role of molecular biology in the management of pancreatic cancer. World J Gastrointest Oncol 2024; 16(7): 2902-2914
URL: https://www.wjgnet.com/1948-5204/full/v16/i7/2902.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i7.2902